compname : Good morning to everyone, everyone.
q4 adjusted earnings per share $1.19.
compname reports q3 non-gaap earnings per share of $0.74.
compname reports 6% revenue growth in q4 of fiscal 2022.
comer corporation's third quarter 2021 outlook, as per new 2020 guidance, remains unchanged.
paraphrase: Let me make a few comments about fy sales.
compname announces quarterly dividend increase of $1 million.
compname reports q2 2021 results and announces additional segmental financial year-end guidance.
sees fy 2019 adjusted earnings per share growth to be primarily driven by increasing opdivo and chandels/treatments.
north american - currently, 2 treatments are expected to be executed in quarter, of which two may be of combination of opdivo and yervoy.
asident asset management - is also important to recognize that mystic trial and checkmate 227 are very different trials.
full year 2022, as discussed above.
q4 adjusted earnings per share $0.22.
compname reports second quarter results.
q2 u.s. pdl-1 positive portion of 1,200 cases increased 8% sequentially.
q4 revenue fell 25 percent, or 1 percent, to $1,100 million versus q3 2021.
